MedTrace Logo

Semaglutide 2.4mg for Low Responders After Bariatric Surgery

NCT06287307 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2024-03-01

No results posted yet for this study

Summary

In 20 - 30% of the patients, the low responders, sufficient weight loss is not achieved after bariatric surgery. Secondary and/or tertiary bariatric procedures can lead to successful weight loss and resolution of comorbid conditions though, morbidity and mortality rates of these procedures are high. Therefore, additional pharmacotherapy has been suggested. Semaglutide is one of the medications that might improve outcome in the post-bariatric population. Semaglutide is a Glucagon-like peptide-1 (GLP-1) receptor analogue developed to treat type 2 diabetes. It causes glucose-dependent insulin secretion, promotes satiety and inhibits glucagon secretion. In obese (non-bariatric) patients, semaglutide has shown to improve glycemic control, decrease blood pressure, lower cardiovascular risk, and decrease body weight.

Conditions

  • Obesity
  • Obesity, Morbid
  • Weight Gain

Interventions

OTHER

Placebo

The placebo will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.

DRUG

Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]

The semaglutide will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.

Sponsors & Collaborators

  • Nederlandse Obestias Kliniek (NOK)

    collaborator UNKNOWN

  • Zuyderland Medisch Centrum

    lead OTHER

Principal Investigators

  • Jan Willem Greve, prof · Zuyderland Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-31
Primary Completion
2026-02-28
Completion
2026-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06287307 on ClinicalTrials.gov